Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans

American Journal of Tropical Medicine and Hygiene

Volumn 85, Issue 4, 2011, Pages 724-731

  Qiao, Ming ^a   Shaw, David ^b   Forrat, Remi ^c   Wartel Tram, Anh ^d   Lang, Jean ^c  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c SANOFI PASTEUR   (France)

^d NONE   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DENGUE VACCINE; NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DENGUE; DENGUE VIRUS 1; DRUG EFFECT; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FLAVIVIRUS; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; IMMUNOGENICITY; INJECTION SITE BLEEDING; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LEUKOCYTE COUNT; LYMPHADENOPATHY; LYMPHOCYTE; MALAISE; MALE; MUSCULOSKELETAL DISEASE; MYALGIA; NEUTROPHIL; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; THROMBOCYTE; UNSPECIFIED SIDE EFFECT; VACCINATION; VIREMIA;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; VERO CELLS; VIRAL VACCINES; YELLOW FEVER VACCINE; YOUNG ADULT;

DENGUE VIRUS; FLAVIVIRUS;

EID: 80052423353     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2011.10-0436     Document Type: Article

References (15)

1. Green S, Rothman A, 2006. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19: 429-436. (Pubitemid 44338101)
2. Kurane I, 2007. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis 30: 329-340. (Pubitemid 47450087)
3. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP, 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74: 5477-5485. (Pubitemid 30346579)
4. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP, 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75: 7290-7304. (Pubitemid 32737987)
5. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J, 2010. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28: 632-649.
6. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J, 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all four serotypes in Flavivirus-naive adults. J Infect Dis 201: 370-377.
7. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, Bedford P, Lang J, Quentin-Millet MJ, Monath TP, 2006. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity. Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2: 60-67. (Pubitemid 43927159)
8. Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, Marchesani R, Knauber M, Wells KH, Arroyo J, Guirakhoo F, 2002. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20: 1004-1018. (Pubitemid 34135935)
9. Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, Chambonneau L, Morrisson DN, Shaw D, Qiao M, Dumas R, Lang J, Forrat R, 2008. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26: 5712-5721.
10. Sanchez V, Gimenez S, Tomlinson B, Chan P, Thomas N, Forrat R, Chambonneau L, Lang J, Guy B, 2006. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 24: 4914-4926. (Pubitemid 43782690)
11. Mantel N, Aguirre M, Gulia S, Girerd-Chambaz Y, Colombani S, Moste C, Barban V, 2008. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 151: 40-46.
12. Porterfield JS, 1959. A plaque technique for the titration of yellow fever virus and antisera. Trans R Soc Trop Med Hyg 53: 458-466.
13. Roehrig JT, Hombach J, Barrett AD, 2008. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21: 123-132. (Pubitemid 351873374)
14. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, Jourdier TM, Ramirez L, Gregoire V, Charnay C, Burdin N, Dumas R, Lang J, 2009. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 80: 302-311.
15. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH, 2011. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 30: e9-e17. doi:10.1097/INF. 0b013e3181fe05af.